JP2006517562A - 選択的ｃｏｘ−２阻害剤としての２，３’−ビピリジン誘導体 - Google Patents

選択的ｃｏｘ−２阻害剤としての２，３’−ビピリジン誘導体 Download PDF

Info

Publication number
JP2006517562A
JP2006517562A JP2006501817A JP2006501817A JP2006517562A JP 2006517562 A JP2006517562 A JP 2006517562A JP 2006501817 A JP2006501817 A JP 2006501817A JP 2006501817 A JP2006501817 A JP 2006501817A JP 2006517562 A JP2006517562 A JP 2006517562A
Authority
JP
Japan
Prior art keywords
cox
compound
disease
treatment
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006501817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517562A5 (https=
Inventor
フアン・フランシスコ・カトゥルラ・ハバロイエス
グレアム・ウォーレロウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall Prodesfarma Sosiedad Anonima
Original Assignee
Almirall Prodesfarma Sosiedad Anonima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma Sosiedad Anonima filed Critical Almirall Prodesfarma Sosiedad Anonima
Publication of JP2006517562A publication Critical patent/JP2006517562A/ja
Publication of JP2006517562A5 publication Critical patent/JP2006517562A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2006501817A 2003-02-13 2004-02-12 選択的ｃｏｘ−２阻害剤としての２，３’−ビピリジン誘導体 Pending JP2006517562A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200300354A ES2214130B1 (es) 2003-02-13 2003-02-13 2-3'-bipiridinas.
PCT/EP2004/001297 WO2004072037A1 (en) 2003-02-13 2004-02-12 2,3'-bipyridines derivatives as selective cox-2 inhibitors

Publications (2)

Publication Number Publication Date
JP2006517562A true JP2006517562A (ja) 2006-07-27
JP2006517562A5 JP2006517562A5 (https=) 2007-03-08

Family

ID=32865135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006501817A Pending JP2006517562A (ja) 2003-02-13 2004-02-12 選択的ｃｏｘ−２阻害剤としての２，３’−ビピリジン誘導体

Country Status (6)

Country Link
US (1) US20060229338A1 (https=)
EP (1) EP1592666A1 (https=)
JP (1) JP2006517562A (https=)
CN (1) CN100408561C (https=)
ES (1) ES2214130B1 (https=)
WO (1) WO2004072037A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
MY163379A (en) * 2010-11-15 2017-09-15 Virdev Intermediates Pvt Ltd A process for cyclooxygenase-2 selective inhibitor
CN103204803A (zh) * 2012-01-13 2013-07-17 阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司 用于合成依托考昔的方法
EP2846793A1 (en) 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
CN104788362A (zh) * 2014-01-21 2015-07-22 济南三元化工有限公司 一种依托考昔或其药学上可接受的盐的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000229A1 (en) * 1999-06-24 2001-01-04 Pharmacia Corporation Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation
JP2005530728A (ja) * 2002-04-05 2005-10-13 カディラ ヘルスケア リミティド 新規複素環式化合物、それらの製剤及びそれらを含む医薬組成物のプロセス、並びに薬剤へのそれらの使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486194B2 (en) * 1993-06-24 2002-11-26 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
IL127441A (en) * 1996-07-18 2003-02-12 Merck Frosst Canada Inc Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
ES2256817T3 (es) * 1997-09-05 2006-07-16 Glaxo Group Limited Composiciones farmaceuticas que comprenden derivados de 2,3-diaril-pirazolo(1,5-b)piridazina.
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
KR100295206B1 (ko) * 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
TW587079B (en) * 1998-09-25 2004-05-11 Almirall Prodesfarma Ag 2-phenylpyran-4-one derivatives
DZ3265A1 (fr) * 1999-04-14 2000-10-19 Pacific Corp Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
DE60006057T2 (de) * 1999-12-03 2004-05-27 Pfizer Products Inc., Groton Heteroarylphenylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
CA2412651A1 (en) * 2000-05-22 2001-11-29 Dr. Reddy's Laboratories Limited Novel compounds having antiinflammatory activity: process for their preparation and pharmaceutical compositions containing them
WO2001091856A2 (en) * 2000-06-01 2001-12-06 Pharmacia Corporation Use of cox2 inhibitors for treating skin injury from exposure to ultraviolet radiation
AU2001282886A1 (en) * 2000-07-13 2002-01-30 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
JP2004505060A (ja) * 2000-07-27 2004-02-19 ファルマシア・コーポレーション 炎症関連心臓血管障害を防止するかまたは治療するためのアルドステロンアンタゴニストおよびシクロオキシゲナーゼ−２阻害剤併用療法
WO2002055502A1 (en) * 2001-01-02 2002-07-18 Fujisawa Pharmaceutical Co., Ltd. Pyridine derivatives useful as cyclooxygenase inhibitor
ES2213485B1 (es) * 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000229A1 (en) * 1999-06-24 2001-01-04 Pharmacia Corporation Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation
JP2005530728A (ja) * 2002-04-05 2005-10-13 カディラ ヘルスケア リミティド 新規複素環式化合物、それらの製剤及びそれらを含む医薬組成物のプロセス、並びに薬剤へのそれらの使用

Also Published As

Publication number Publication date
ES2214130B1 (es) 2005-12-01
CN100408561C (zh) 2008-08-06
ES2214130A1 (es) 2004-09-01
WO2004072037A8 (en) 2005-09-29
EP1592666A1 (en) 2005-11-09
WO2004072037A1 (en) 2004-08-26
US20060229338A1 (en) 2006-10-12
CN1774422A (zh) 2006-05-17

Similar Documents

Publication Publication Date Title
US5596008A (en) 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5001136A (en) Leukotriene-synthesis-inhibiting 2-substitutedmethylamino-5-(hydroxy or alkoxy)pyridines
CN105829286B (zh) 作为lta4h抑制剂的杂芳基丁酸衍生物
US20090170903A1 (en) Ester derivatives as phosphodiesterase inhibitors
JP2003501464A (ja) シクロオキシゲナーゼ−２の阻害剤としての１−（４−スルファミルアリール）−３−置換−５−アリール−２−ピラゾリン
JPH11501049A (ja) イミダゾ〔１，２−ａ〕ピリジン誘導体
TW200813010A (en) Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
CN110872285A (zh) 作为受体相互作用蛋白1(rip1)激酶抑制剂的杂环化合物
KR100437307B1 (ko) 토라세미드의 새로운 결정 변형태 ⅲ
JP2005511602A (ja) アントラニル酸アミドおよびｖｅｇｆ受容体チロシンキナーゼ阻害剤としてのその使用
JPH08504803A (ja) スクアレンシンターゼ阻害物質としてのキヌクリジン誘導体
JP4480894B2 (ja) 抗炎症活性を有する新規なイミダゾール類
HUP0104620A2 (hu) 2-Fenil-pirán-4-on-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
JP2006517562A (ja) 選択的ｃｏｘ−２阻害剤としての２，３’−ビピリジン誘導体
JPS58110567A (ja) 新規４−（１−ヒドロキシル−２−〔（アシルアミノ）アルキルアミノ〕エチル）フエノ−ルのエステル、その製造法及びこれを含有する局所的消炎症性製薬組成物
US9079876B2 (en) Imidazole derivatives and preparation method and use thereof
JP2006517561A (ja) Ｃｏｘ−２阻害剤としての３−フェニルフラン−２−オン誘導体
BRPI0418306B1 (pt) composto n-[(1s,1ar,7br)-4,7-difluoro-1,1a,2,7b-tetraidrociclopropa[c]cromen-1-il]-n’-[5-(4-(sulfonamido)fenoxi)-2-piridinil]ureia, composição farmacêutica e uso do dito composto para profilaxia ou tratamento de infecções por hiv-1
WO2000077003A1 (en) Optically active pyrrolopyridazine compounds
MXPA02009322A (es) Nuevos derivados de imidazol con actividad antiinflamatoria.
CZ20021382A3 (cs) Deriváty fenyl- a pyridyl-tetrahydropyridinu, způsob jejich přípravy a farmaceutická kompozice, která je obsahuje
JP3977222B2 (ja) シクロオキシゲナーゼ−２阻害剤として選択性の優れた３，４−ジヒドロ−１ｈ−ナフタレン誘導体
CN100436438C (zh) 2-苯基吡喃-4-酮衍生物作为环加氧酶-2的抑制剂
JP2003527389A (ja) ２−フェニルピラン−４−オン誘導体
CN121517394A (zh) 一种取代的吡啶丙酸衍生物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101116